Evolus (NASDAQ:EOLS) is up 3% premarket on light volume in reaction to its announcement of results from a Korea-based Phase 3 head-to-head study comparing Jeuveau (prabotulinumtoxinA-xvfs) to Allergan’s (NYSE:AGN) Botox (onabotulinumtoxinA) for the treatment of frown lines. The data were just published in the journal Dermatologic Surgery.
The study met the primary endpoint demonstrating
the non-inferiority of prabotulinumtoxinA to onabotulinumtoxinA as
measured by the proportion of patients with Grade 0 or 1 severity of
crow’s feet at maximum smile at week 4.
The FDA approved Jeuveau about a year ago.
Related ticker: AbbVie (NYSE:ABBV)
https://seekingalpha.com/news/3534687-evolus-jeuveau-matches-botox-in-study-shares-up-3-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.